Abstract
We conducted a phase I clinical trial (clinicaltrials.gov identifier, NCT00641017) of the experimental live-attenuated human parainfluenza virus type 1 (HPIV-1) vaccine rHPIV-1/84/del 170/942A sequentially in 3 groups: Adults, HPIV-1-seropositive children, and HPIV-1-seronegative children, the target population for vaccination. rHPIV-1/84/del 170/942A was appropriately restricted in replication in adults and HPIV-1-seropositive children but was overattenuated (ie, insufficiently infectious and immunogenic) for HPIV-1-seronegative children.
Author supplied keywords
Cite
CITATION STYLE
Karron, R. A., Mateo, J. S., Thumar, B., Schaap-Nutt, A., Buchholz, U. J., Schmidt, A. C., … Collins, P. L. (2015). Evaluation of a live-attenuated human parainfluenza type 1 vaccine in adults and children. Journal of the Pediatric Infectious Diseases Society, 4(4), e143–e146. https://doi.org/10.1093/jpids/piu104
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
